11:36 AM EDT, 03/25/2024 (MT Newswires) -- Zentek ( ZTEK ) said Monday a preclinical study by its Triera Biosciences unit of C19HBA showed that this potential therapeutic for COVID-19 has a "promising" safety and toxicity profile.

An inflammatory cell infiltration study and analysis of a full cytokine panel showed that C19HBA "appears to be safe and well-tolerated in mice both before and after SARS-CoV-2 infection," the company said.

"Although further work is required, this data supports that our aptamer platform is safe and works in a manner that we expected," Chief Executive Greg Fenton said.

Price: 1.28, Change: -0.01, Percent Change: -1.11